These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Association of somatic mutations in BRCA2 BRC domain with chemotherapy sensitivity and survival in high grade serous ovarian cancer. Zhang G; Zhang J; Zhu Y; Liu H; Shi Y; Mi K; Li M; Zhao Q; Huang Z; Huang J Exp Cell Res; 2021 Sep; 406(1):112742. PubMed ID: 34302857 [TBL] [Abstract][Full Text] [Related]
3. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259 [TBL] [Abstract][Full Text] [Related]
4. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. Zhong Q; Peng HL; Zhao X; Zhang L; Hwang WT Clin Cancer Res; 2015 Jan; 21(1):211-20. PubMed ID: 25348513 [TBL] [Abstract][Full Text] [Related]
5. Survival Benefit of Germline BRCA Mutation is Associated with Residual Disease in Ovarian Cancer. Shi T; Wang P; Tang W; Jiang R; Yin S; Shi D; Wang Q; Wei Q; Zang R Cell Physiol Biochem; 2018; 47(5):2088-2096. PubMed ID: 29975922 [TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis. Xu K; Yang S; Zhao Y Oncotarget; 2017 Jan; 8(1):285-302. PubMed ID: 27690218 [TBL] [Abstract][Full Text] [Related]
7. Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations. Birkbak NJ; Kochupurakkal B; Izarzugaza JM; Eklund AC; Li Y; Liu J; Szallasi Z; Matulonis UA; Richardson AL; Iglehart JD; Wang ZC PLoS One; 2013; 8(11):e80023. PubMed ID: 24265793 [TBL] [Abstract][Full Text] [Related]
8. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175 [TBL] [Abstract][Full Text] [Related]
10. Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis. Labidi-Galy SI; Rodrigues M; Sandoval JL; Kurtz JE; Heitz F; Mosconi AM; Romero I; Denison U; Nagao S; Vergote I; Parma G; Nøttrup TJ; Rouleau E; Garnier G; El-Balat A; Zamagni C; Martín-Lorente C; Pujade-Lauraine E; Fiévet A; Ray-Coquard IL Ann Oncol; 2023 Feb; 34(2):152-162. PubMed ID: 36564284 [TBL] [Abstract][Full Text] [Related]
11. Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis. Sabatier R; Lavit E; Moretta J; Lambaudie E; Noguchi T; Eisinger F; Cherau E; Provansal M; Livon D; Rabayrol L; Popovici C; Charaffe-Jauffret E; Sobol H; Viens P Fam Cancer; 2016 Oct; 15(4):497-506. PubMed ID: 26833043 [TBL] [Abstract][Full Text] [Related]
12. Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea. Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS Cancer Res Treat; 2020 Oct; 52(4):1229-1241. PubMed ID: 32718143 [TBL] [Abstract][Full Text] [Related]
13. Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer. Lee YJ; Kim HS; Rim JH; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT BMC Cancer; 2020 Mar; 20(1):185. PubMed ID: 32131779 [TBL] [Abstract][Full Text] [Related]
14. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. Yang D; Khan S; Sun Y; Hess K; Shmulevich I; Sood AK; Zhang W JAMA; 2011 Oct; 306(14):1557-65. PubMed ID: 21990299 [TBL] [Abstract][Full Text] [Related]
15. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976 [TBL] [Abstract][Full Text] [Related]
16. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer. Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392 [TBL] [Abstract][Full Text] [Related]
17. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study. de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974 [TBL] [Abstract][Full Text] [Related]
19. Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients. Sun J; Meng H; Yao L; Lv M; Bai J; Zhang J; Wang L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y Clin Cancer Res; 2017 Oct; 23(20):6113-6119. PubMed ID: 28724667 [No Abstract] [Full Text] [Related]
20. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis. Le Page C; Rahimi K; Rodrigues M; Heinzelmann-Schwarz V; Recio N; Tommasi S; Bataillon G; Portelance L; Golmard L; Meunier L; Tonin PN; Gotlieb W; Yasmeen A; Ray-Coquard I; Labidi-Galy SI; Provencher D; Mes-Masson AM Gynecol Oncol; 2020 Feb; 156(2):377-386. PubMed ID: 31753525 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]